Literature DB >> 15048899

Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.

John McConville1, Maria Elena Farrugia, David Beeson, Uday Kishore, Richard Metcalfe, John Newsom-Davis, Angela Vincent.   

Abstract

Antibodies to rat muscle specific kinase, MuSK, have recently been identified in some generalized "seronegative" myasthenia gravis (SNMG) patients, who are often females with marked bulbar symptoms. Using immunoprecipitation of (125)I-labelled-human MuSK, 27 of 66 (41%) seronegative patients were positive, but 18 ocular SNMG patients, 105 AChR antibody positive MG patients, and 108 controls were negative. The antibodies are of high affinity (Kds around 100 pM) with titers between 1 and 200 nM. They bind to the extracellular Ig-like domains of soluble or native MuSK. Surprisingly they are predominantly in the IgG4 subclass. MuSK-antibody associated MG may be different in etiological and pathological mechanisms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15048899     DOI: 10.1002/ana.20061

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  93 in total

1.  Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis.

Authors:  Fredrik Romi; Shigeaki Suzuki; Norihiro Suzuki; Axel Petzold; Gordon T Plant; Nils Erik Gilhus
Journal:  J Neurol       Date:  2011-12-14       Impact factor: 4.849

Review 2.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 3.  Current topics in therapeutic plasmapheresis.

Authors:  Takeshi Nakanishi; Naoki Suzuki; Takahiro Kuragano; Yasuyuki Nagasawa; Yukiko Hasuike
Journal:  Clin Exp Nephrol       Date:  2013-07-26       Impact factor: 2.801

4.  Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status.

Authors:  Maria I Leite; Margaret Jones; Philipp Ströbel; Alexander Marx; Ralf Gold; Erik Niks; Jan J G M Verschuuren; Sonia Berrih-Aknin; Francesco Scaravilli; Aurea Canelhas; B Paul Morgan; Angela Vincent; Nick Willcox
Journal:  Am J Pathol       Date:  2007-08-03       Impact factor: 4.307

5.  MuSK-antibody positive pure ocular myasthenia gravis.

Authors:  Frank Hanisch; Katharina Eger; Stephan Zierz
Journal:  J Neurol       Date:  2005-11-29       Impact factor: 4.849

6.  Ocular myasthenia: a rare presentation with MuSK antibody and bilateral extraocular muscle atrophy.

Authors:  Jane W Chan; William W Orrison
Journal:  Br J Ophthalmol       Date:  2007-06       Impact factor: 4.638

7.  Animal models of antimuscle-specific kinase myasthenia.

Authors:  David P Richman; Kayoko Nishi; Michael J Ferns; Joachim Schnier; Peter Pytel; Ricardo A Maselli; Mark A Agius
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

Review 8.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

Review 9.  The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.

Authors:  Inga Koneczny; Judith Cossins; Angela Vincent
Journal:  J Anat       Date:  2013-03-04       Impact factor: 2.610

Review 10.  [Myasthenia gravis and myasthenic syndromes].

Authors:  W Marouf; J P Sieb
Journal:  Z Rheumatol       Date:  2009-08       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.